Cibc Asset Management Inc Revance Therapeutics, Inc. Transaction History

Cibc Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$4.65 - $9.31 $2.76 Million - $5.52 Million	593,224 Added 51.71%	1,740,518 $8.56 Million
Q4 2023 Feb 13, 2024	BUY	$5.81 - $11.2 $4.77 Million - $9.19 Million	820,587 Added 251.17%	1,147,294 $10.1 Million
Q3 2023 Oct 30, 2023	BUY	$11.47 - $25.07 $1.07 Million - $2.35 Million	93,701 Added 40.21%	326,707 $3.75 Million
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $156,548 - $238,372	6,338 Added 2.8%	233,006 $5.9 Million
Q1 2023 May 12, 2023	SELL	$18.36 - $35.27 $3.4 Million - $6.53 Million	-185,169 Reduced 44.96%	226,668 $7.3 Million
Q4 2022 Feb 13, 2023	SELL	$18.32 - $30.66 $1.64 Million - $2.74 Million	-89,332 Reduced 17.82%	411,837 $7.6 Million
Q3 2022 Nov 03, 2022	BUY	$14.33 - $28.47 $7.18 Million - $14.3 Million	501,169 New	501,169 $13.5 Million
Q2 2022 Aug 09, 2022	SELL	$11.52 - $20.4 $5.42 Million - $9.6 Million	-470,819 Closed	0 $0
Q1 2022 May 06, 2022	SELL	$12.36 - $20.31 $338,787 - $556,697	-27,410 Reduced 5.5%	470,819 $9.18 Million
Q4 2021 Feb 08, 2022	BUY	$12.46 - $27.87 $6.21 Million - $13.9 Million	498,229 New	498,229 $8.13 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.